FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

Study ID
NCT01328171

Study type
Interventional

Study phase
Phase 2

Study status
Active, not recruiting

Trial Acronym

VOLFI

Trial Summary

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI

More informations

Trial Starting Date

Apr 30,2011

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

In order to facilitate the use of our website, we use cookies.